Contineum Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2023 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Contineum Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2023 to Q4 2024.
  • Contineum Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$17M, a 76.2% decline year-over-year.
  • Contineum Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$50.9M, a 417% decline year-over-year.
  • Contineum Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$50.9M, a 417% decline from 2023.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$50.9M -$17M -$7.37M -76.2% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-06
Q3 2024 -$43.5M -$13M -$4.91M -60.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$38.6M -$10.9M -$49.9M -128% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $11.3M -$9.93M -$4.82M -94.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-16
Q4 2023 $16.1M -$9.68M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-06
Q3 2023 -$8.07M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $38.9M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$5.12M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.